vimarsana.com

Page 51 - சர்வதேச கூட்டமைப்பு ஆஃப் மருந்து உற்பத்தியாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID-19 vaccine equity: Campaigners say onus on pharma companies to start sharing IP and to transfer technology

Rows about vaccine supply and threats of export blocks don’t do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level. David McNair, executive director for global policy at The ONE Campaign said: “ This is a global crisis that crosses every border, with the threat of new, more virulent strains increasing the risk to us all. Either we beat the virus together or we don’t beat it at all, so we urge all parties to resolve these differences.”​ Collaboration is required, he said, to massively increase the supply of vital vaccines and to help develop a truly global approach in tackling the virus, in all countries.

Coronavirus: What if vaccines aren t enough for herd immunity?

With vaccination programmes being rolled out by countries around the world, it seem the tables have finally turned in the fight against the novel coronavirus. These problems will face even the richest economies. A survey in Hong Kong this week found that more than half of residents did not intend to take Covid-19 jabs. This poses particular problems for poorer.

The Sanofi-BioNTech Covid-19 vaccine partnership is unprecedented — Quartz

January 29, 2021 Cooperative manufacturing isn’t unheard of in the pharmaceutical world, but it’s not common. The demands of the Covid-19 pandemic, however, have turned rival companies into manufacturing allies. On Jan. 27, the French drug company Sanofi announced that it would help BioNTech manufacture some 125 million doses of its mRNA-based Covid-19 vaccine for the European Union (EU). This collaboration is unique in the pharmaceutical industry: Sanofi and BioNTech are direct competitors in the vaccine world, the former still hoping to launch its own Covid-19 vaccine within the year. But they’re not alone. AstraZeneca, which has been criticized for its slow pace of vaccine production in the EU, partnered with JCR Pharmaceuticals in Japan and the Serum Institute of India to ramp up manufacturing. Moderna has partnered with the Swiss chemical company Lonza Group AG to manufacture vaccines and is seeking other partners, Bloomberg reports.

R&D lacking on emerging infectious diseases, report finds

Putin s new vision of anarchy, world war and the Russian Dream

POLITICO Get the Global Translations newsletter Email Sign Up By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Please send your tips and thoughts to [email protected] Mark Carney. Climate is also President Joe Biden s theme of the day: he will issue a slate of executive orders designed to make climate change a national security priority and reshaping the U.S. oil and gas industry.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.